Abstract：Objective To study thyroid functional status of the aged patients with malignant tumors and the relationship between thyroid function with chemotherapy. Methods 398 aged patients with malignant tumors were recruited as the pathological group. At the same time, 400 aged healthg subjects served as the control group. The thyroid hormones (thyroid hormone, TH), and thyrotropin (thyroid stimulating hormone, TSH) levels were measured. The thyroid function in the groups was analyzed and compared. When KPS score is over 60, the aged patients with malignant tumors in normal hormone levels were divided into the observation group (132 cases) and the control group (129 cases).Two groups had no significant difference in the age and KPS score. The patients in the observation group were treated by chemotherapy and TH and TSH levels observed before treatment and 6 moths post-treatment. The patients in the control group were given symptomatic treatment, TH and TSH levels were observed over the same period. We compared thyroid hormone and thyroid hormone levels and analyzed the relationship between thyroid function with chemotherapy in the aged patients with malignant tumor. Results The thyroid hormone and thyroid stimulating hormone in 398 aged patients with malignant tumor were compared with those in the healthy control group, the difference was not statistically significant (P＜0.05). The aged patients with malignant tumors in normal hormone levels were divided into the observation group and the control group. In observation group the hypothyroidism (hypothyroidism) ratio was 7.58%, the proportion of subclinical hypothyroidism was 23.48%, hyperthyroidism (hyperthyroidism) ratio was 1.51%, and subclinical hyperthyroidism ratio was 2.27%. In control group, the proportion of hypothyroidism was 5.65%, subclinical hypothyroidism ratio was 5.65%, hyperthyroidism ratio was 1.61% and subclinical hyperthyroidism ratio was 3.23%. In the observation group, the thyroid disease incidence rate was higher. Incidence of subclinical hypothyroidism in the two groups was significantly different (P＜0.05). Conclusions The thyroid dysfunction in the aged patients with malignant tumor was not significantly different compared with the health control group. Chemotherapy in the aged patients with malignant tumor harms the thyroid function to some extent. The detection of thyroid function in the aged patients with malignant tumor has clinical significance.
邹春华,黄涛金,谢勇久,林争,王绎,明华. 老年恶性肿瘤患者甲状腺功能状态及化学药物疗法对其的影响[J]. 武警医学, 2014, 25(12): 1225-1227.
ZOU Chunhua,HUANG Taojin,XIE Yongjiu,LIN Zheng,WANG Yi,and MING Hua. Thyroid functional status in aged patients with malignant tumors and relationship with chemotherapy. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(12): 1225-1227.
Sabatier R, Eymard J C, Walz J, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? [J]. AnnOncol, 2012,23(3):714-721.
[1]
Hellevik A I, Asvold B O, Bjro T, et al. Thyroid function and cancer risk: a prospective population study [J]. Cancer Epidemiol Biomarkers Prev, 2009, 18(2):570-574.
[8]
Clemons J, Gao D, Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib[J]. Clin Genitourin Cancer, 2012, 10(4):225-231.
[2]
Moeller L C, Führer D.Thyroid hormone, thyroid hormone, receptors, and cancer: a clinical perspective [J]. Endocr Relat Cancer, 2013, 20(2):19-29.
[3]
Huang J, Jin L, Ji G, et al. Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine[J]. BMC Cancer, 2013,13:334.
[9]
Hamnvik O P, Larsen P R, Marqusee E. Thyroid dysfunction from antineoplastic agents [J]. J Natl Cancer Inst, 2011, 103(21):572-1587.
[4]
Cooper D S, Biondi B. Subclinical thyroid disease [J]. Lancet, 2012, 379(9821): 1142-1154.
[10]
Nelson M, Hercbergs A, Rybicki L, et al.Association between development of hypothyroidism and improved survival in patients with head and neck cancer[J]. Arch Otolaryngol Head Neck Surg, 2006,132(10):1041-1046.
Sabatier R, Eymard J C, Walz J, et al. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? [J]. AnnOncol, 2012,23(3):714-721.
[8]
Clemons J, Gao D, Naam M, et al. Thyroid dysfunction in patients treated with sunitinib or sorafenib[J]. Clin Genitourin Cancer, 2012, 10(4):225-231.
[9]
Hamnvik O P, Larsen P R, Marqusee E. Thyroid dysfunction from antineoplastic agents [J]. J Natl Cancer Inst, 2011, 103(21):572-1587.
[10]
Nelson M, Hercbergs A, Rybicki L, et al.Association between development of hypothyroidism and improved survival in patients with head and neck cancer[J]. Arch Otolaryngol Head Neck Surg, 2006,132(10):1041-1046.
2014, Vol. 25 
